ROKIT HEALTHCARE to Pay 1.32 Billion Won Advance for FDA-Approved Raw Material Adinizer, Strengthening Supply Chain and Shareholder Value
ROKIT HEALTHCARE decided to pay an advance of 1.32 billion KRW to BSL for a non-exclusive supply contract of 'Adinizer', an FDA-approved key raw material.
The advance accounts for 11.42% of the company's equity capital (115.54 billion KRW) and will be settled against future product payments.
This move aims to secure a stable supply of critical material, reducing procurement risk and supporting the company's core business operations.
The payment was approved on April 15, 2026, with board resolution attended by two outside directors and an auditor.
[AI Summary]ROKIT HEALTHCARE's decision to pay an advance of 1.32 billion KRW (11.42% of equity) for FDA-approved raw material Adinizer is a strategic move to mitigate supply chain risk and enhance core business competitiveness. While it creates short-term cash outflow, it is expected to positively impact shareholder value through improved long-term profitability.